ALNYLAM PHARMACEUTICALS, INC.: basic weighted-average shares
Basic weighted-average shares for ALNYLAM PHARMACEUTICALS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All ALNYLAM PHARMACEUTICALS, INC. financial histories
What this measure means
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
Exact concept: us-gaap:WeightedAverageNumberOfSharesOutstandingBasic. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 131,004,000 | shares | 2026-02-12 | 10-K · 0001628280-26-007497 |
| 2024-01-01 | 2024-12-31 | 127,651,000 | shares | 2026-02-12 | 10-K · 0001628280-26-007497 |
| 2023-01-01 | 2023-12-31 | 124,906,000 | shares | 2026-02-12 | 10-K · 0001628280-26-007497 |
| 2022-01-01 | 2022-12-31 | 121,689,000 | shares | 2025-02-13 | 10-K · 0001178670-25-000026 |
| 2021-01-01 | 2021-12-31 | 118,451,000 | shares | 2024-02-15 | 10-K · 0001178670-24-000008 |
| 2020-01-01 | 2020-12-31 | 114,986,000 | shares | 2023-02-23 | 10-K · 0001178670-23-000005 |
| 2019-01-01 | 2019-12-31 | 109,264,000 | shares | 2022-02-10 | 10-K · 0001178670-22-000013 |
Related financial histories
- ALNYLAM PHARMACEUTICALS, INC.: total assets
- ALNYLAM PHARMACEUTICALS, INC.: total liabilities
- ALNYLAM PHARMACEUTICALS, INC.: stockholders equity
- ALNYLAM PHARMACEUTICALS, INC.: cash and cash equivalents
- ALNYLAM PHARMACEUTICALS, INC.: net income or loss
- ALNYLAM PHARMACEUTICALS, INC.: operating cash flow
- ALNYLAM PHARMACEUTICALS, INC.: capital expenditure payments
- ALNYLAM PHARMACEUTICALS, INC.: revenue
- ALNYLAM PHARMACEUTICALS, INC.: contract revenue excluding tax
- ALNYLAM PHARMACEUTICALS, INC.: financing cash flow
- ALNYLAM PHARMACEUTICALS, INC.: investing cash flow
- ALNYLAM PHARMACEUTICALS, INC.: retained earnings or deficit
- ALNYLAM PHARMACEUTICALS, INC.: diluted weighted-average shares
- ALNYLAM PHARMACEUTICALS, INC.: basic earnings per share
- ALNYLAM PHARMACEUTICALS, INC.: diluted earnings per share
- ALNYLAM PHARMACEUTICALS, INC.: income tax expense or benefit
- ALNYLAM PHARMACEUTICALS, INC.: net property, plant and equipment
- ALNYLAM PHARMACEUTICALS, INC.: share-based compensation expense
- ALNYLAM PHARMACEUTICALS, INC.: operating income or loss
- ALNYLAM PHARMACEUTICALS, INC.: current assets
- ALNYLAM PHARMACEUTICALS, INC.: interest expense
- ALNYLAM PHARMACEUTICALS, INC.: current liabilities
- ALNYLAM PHARMACEUTICALS, INC.: current accounts payable
- ALNYLAM PHARMACEUTICALS, INC.: net finite-lived intangible assets
- ALNYLAM PHARMACEUTICALS, INC.: net current accounts receivable
- ALNYLAM PHARMACEUTICALS, INC.: operating expenses
- ALNYLAM PHARMACEUTICALS, INC.: net inventory
- ALNYLAM PHARMACEUTICALS, INC.: selling, general and administrative expense
- ALNYLAM PHARMACEUTICALS, INC.: research and development expense
Inspect the source
- Entity
- ALNYLAM PHARMACEUTICALS, INC. / CIK 0001178670
- Captured
- 2026-09-20T07:45:03.960Z
- SEC response SHA-256
bd72ebc4b5a116f8e743e4d6f33178d8af2533ff852a0cd94d52307715b0cbd0
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001178670.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))